Previously, it was shown that induction of neutralizing antibodies against EBV gp350, the vial envelope protein that mediates attachment via complement receptors (e.g., CD21) to human B cells, reduced the incidence of symptomatic primary EBV infection (infectious mononucleosis) by 78% [198,200]. The gene discussed is CR2; the disease is Epstein-Barr virus infection.